“At Grünenthal we exploit devices and technologies to provide innovative solutions for patients in need.”
Traditional techniques for managing surgical incisions do not always deliver the high level of performance that patients and surgeons demand. 20 percent of patients who undergo gastrointestinal surgery, for example, are affected by postoperative intestinal leakage1. A complication that can be life-threatening. Furthermore, surgical wound infection, one of the consequence of poor wound healing, affects over 500,000 patients per year in the US and leads to about 8,000 deaths annually2. Understandably, these numbers are a source of stress and anxiety for patients and their families.
To tackle these problems, our medical device experts are developing innovative surgical glues that provide a unprecedent combination of technical characteristics tailored to assist surgeons in optimizing the patient recovery. This combination of attributes enables application to a wide range of procedures – either topical or inside the body.
The first product from this innovative platform is FLIX®, which has been granted CE-Certification in Europe in January 2018. The second product will be VIVO, an alternative version for in-body-application – cardiovascular and gastrointestinal. It is one the very few surgical glues that can be used inside the body and we are proud that the FDA has already acknowledged its potential by granting Expedited Access Pathway (EAP) to speed up its approval process.
Our technology platform has the potential to transform surgical wound sealing – and give patients peace of mind as they can focus on their recovery. #changeispossible
1 Alberts, et al. Predicting risk and diminishing the consequences of anastomotic dehiscence following rectal resection. Colorectal Dissection, September 2003.
2 Najar PA, Smink DS. Prophylactic antibiotics and prevention of surgical site infections. Surg Clin N Am 2015;95: 269-83